Drugs & TargetsFree Servier to acquire Agios Pharmaceuticals’ oncology business January 08, 2021Vol.47 No.01
Drugs & TargetsFree Kite and Oxford BioTherapeutics establish cell therapy research collaboration in blood cancers and solid tumors January 08, 2021Vol.47 No.01
Drugs & Targets FDA issues a guidance on quality standards of the Mammography Quality Standards Act during COVID-19 December 11, 2020Vol.46 No.46
Drugs & Targets Amgen and McKesson collaborate to advance cancer innovation in communities December 11, 2020Vol.46 No.46
Drugs & Targets Danyelza receives FDA approval for treatment of neuroblastoma December 04, 2020Vol.46 No.45
Drugs & Targets Gavreto receives FDA approval for RET-altered thyroid cancers December 04, 2020Vol.46 No.45
Drugs & Targets FDA approves first PSMA-targeted PET imaging drug for in prostate cancer December 04, 2020Vol.46 No.45
Drugs & Targets European Commission approves Opdivo as second-line treatment for unresectable advanced, recurrent or metastatic ESCC December 04, 2020Vol.46 No.45
Drugs & Targets EMA validates tepotinib application for treatment of advanced NSCLC with METex14 skipping alterations December 04, 2020Vol.46 No.45
Drugs & TargetsFree Keytruda receives accelerated approval from FDA for locally recurrent, unresectable or metastatic TNBC November 20, 2020Vol.46 No.44
